Nivolumab‐induced plaque morphea in a malign melanoma patient
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cosmetic Dermatology"
DOI: 10.1111/jocd.13914
Abstract: Nivolumab is one of the targeted cancer therapy agent that acts to increase the immune responses by inhibition of antiprogrammed‐death‐receptor 1, which is one of the check points of the immune response. Nivolumab can be… read more here.
Keywords: plaque morphea; induced plaque; malign; morphea malign ... See more keywords